Onconetix, Inc. (ONCO)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 0.1442 |
| Open | 0.1400 |
| Bid | 0.1459 x 100 |
| Ask | 0.1480 x 100 |
| Day's range | 0.1400 - 0.1500 |
| 52-week range | 0.1000 - 1.2100 |
| Volume | |
| Avg. volume | 4,455,322 |
| Market cap | 3.148M |
| Beta (5Y monthly) | 3.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 20 May 2024 - 24 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
CINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and patients in oncology, today announced the appointment of Ajit Singh, Ph.D. and Thomas Meier, Ph.D. to its Board of Directors. “We are thrilled to announce the addition of Dr. Singh and Dr. Meier to the Board of Directors of Onconetix,” stated Chair
© 2024 Yahoo. All rights reserved.